Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.68 |
| ▸ | FADS1 | O60427 | 1/20 | 0.50 |
| ▸ | CES2 | O00748 | 2/20 | 0.47 |
| ▸ | CES1 | P23141 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | BRAF | P15056 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29467969 | 1.00 | KEAP1 (0.68) | KEAP1FADS1CES2CES1ALDH1A1 | |
| SCHEMBL18070541 | 0.85 | KDM4E (0.53) | KEAP1HDAC1KMT2AKDM4EGFER | |
| SCHEMBL30590455 | 0.83 | KEAP1 (0.52) | KEAP1FADS1CES2CES1ALDH1A1 | |
| SCHEMBL1720983 | 0.83 | KEAP1 (0.52) | KEAP1FADS1CES2CES1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL4049299 | 0.82 | KEAP1 (0.50) | KEAP1FADS1CES2CES1ALDH1A1 | |
| SCHEMBL183930 | 0.81 | KEAP1 (0.70) | KEAP1FADS1CES2CES1ALDH1A1 | |
| SCHEMBL135091 | 0.81 | KEAP1 (1.00) | KEAP1FADS1CES2CES1ALDH1A1 | |
| SCHEMBL29364785 | 0.81 | KEAP1 (1.00) | KEAP1FADS1CES2CES1ALDH1A1 | |
| SCHEMBL31230207 | 0.81 | KEAP1 (0.70) | KEAP1FADS1CES2CES1ALDH1A1 | |
| SCHEMBL12789530 | 0.81 | BRAF (0.61) | KEAP1HDAC1BRAFHDAC3HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117550981-B | Preparation method of 2-amino-5-fluoro acetophenone | 成都工业学院 | 2024-03-15 | — | — | CN | claimed |
| CN-117550981-A | Preparation method of 2-amino-5-fluoro acetophenone | 成都工业学院 | 2024-02-13 | — | — | CN | claimed |
| CN-109384683-B | Preparation method of 2-amino-5-fluoroacetophenone | 杭州科耀医药科技有限公司 | 2021-09-03 | — | — | CN | claimed |
| CN-110922315-A | Preparation method of Laolatinib intermediate compound | 常州工学院 | 2020-03-27 | — | — | CN | claimed |
| EP-0195396-B1 | 5-FLUOROBENZONITRILE DERIVATIVES AND PHARMACOLOGICALLY ACCEPTABLE ACID ADDITION SALTS THEREOF FOR INCREASING THE LEAN MEAT TO FAT RATIO, AND/OR ENHANCING THE GROWTH RATE OF WARM-BLOODED ANIMALS | AMERICAN CYANAMID COMPANY (US) | 1989-03-01 | — | — | EP | claimed |
| EP-0195396-A1 | 5-Fluorobenzonitrile derivatives and pharmacologically acceptable acid addition salts thereof for increasing the lean meat to fat ratio, and/or enhancing the growth rate of warm-blooded animals | AMERICAN CYANAMID COMPANY (US) | 1986-09-24 | — | — | EP | claimed |
| US-20260008774-A1 | QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS INC (US) | 2026-01-08 | — | — | US | disclosed |
| US-20250368647-A1 | NITROGEN CONTAINING CONDENSED 2,3-DIHYDROQUINAZOLINONE COMPOUNDS AS NAV1.8 INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2025-12-04 | — | — | US | disclosed |
| WO-2025235686-A1 | FLUOROCAMPTOTHECIN COMPOUNDS, CONJUGATES, AND METHODS THEREOF | Aarvik Therapeutics, Inc. (US) | 2025-11-13 | — | — | WO | disclosed |
| US-12448369-B2 | Quinolinone amide compounds and uses thereof | EDGEWISE THERAPEUTICS, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| US-20250179072-A1 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2025-06-05 | — | — | US | disclosed |
| CN-120058540-A | Method for preparing halogenated 2-aminobenzophenone by continuous photochemical rearrangement | 姚昕辰 | 2025-05-30 | — | — | CN | disclosed |
| WO-2025077773-A1 | NOVEL TYPE I TOPOISOMERASE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翊维康医药有限责任公司 | 2025-04-17 | — | — | WO | disclosed |
| US-4656267-A | RENAL VASODILATORS, CARDIOVASCULAR AGENTS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1987-04-07 | — | — | US | disclosed |
| US-4622065-A | HERBICIDES | PPG INDUSTRIES, INC. (US) | 1986-11-11 | — | — | US | disclosed |
| US-4614746-A | 5-fluorobenzonitrile derivatives for increasing the lean meat to fat ratio and/or enhancing the growth rate of warm-blooded animals | AMERICAN CYANAMID COMPANY (US) | 1986-09-30 | — | — | US | disclosed |
| EP-0195396-A1 | 5-Fluorobenzonitrile derivatives and pharmacologically acceptable acid addition salts thereof for increasing the lean meat to fat ratio, and/or enhancing the growth rate of warm-blooded animals | AMERICAN CYANAMID COMPANY (US) | 1986-09-24 | — | — | EP | disclosed |
| US-4555571-A | Substituted 2(1H)-quinazolinone-1-alkanoic acids and esters | ORTHO PHARMACEUTICAL CORPORATION (US) | 1985-11-26 | — | — | US | disclosed |
| EP-0138491-A2 | Substituted 2(1H)-quinazolinone-1-alkanoic acids and esters | ORTHO PHARMACEUTICAL CORPORATION (US) | 1985-04-24 | — | — | EP | disclosed |
| US-3987047-A | ANORETICS | BOEHRINGER INGELHEIM GMBH (DT) | 1976-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12448369-B2 | Quinolinone amide compounds and uses thereof | TNNI3, TNNT2, COQ8A | KEAP1 555/4885FADS1 408/4885CES2 894/4885 |
| US-20250368647-A1 | NITROGEN CONTAINING CONDENSED 2,3-DIHYDROQUINAZOLINONE COMPOUNDS AS NAV1.8 INHIBITORS | SCN8A, SCN2A, SCN5A | KEAP1 1018/4885FADS1 2629/4885CES2 3401/4885 |
| US-20250179072-A1 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | AKR1C2, AKR1B1, AKR1C1 | KEAP1 247/4885FADS1 319/4885CES2 965/4885 |
| US-20260008774-A1 | QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF | TNNT2, TNNI3, TNNC1 | KEAP1 1335/4885FADS1 1586/4885CES2 632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.